Latanoprost
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1996
- First approval year
- 1996
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Latanoprost
- Molecular weight
- 432.6
- Structure (SMILES)
- CC(C)OC(=O)CCC/C=C\C[C@@H]1[C@@H](CC[C@@H](O)CCc2ccccc2)[C@H](O)C[C@@H]1O
- catiolanze
- Catiolanze
- iyuzeh
- Iyuzeh
- latanoprost
- Latanoprost
- latanoprost component of rocklatan
- Latanoprost component of rocklatan
- latanoprost component of xalacom
- Latanoprost component of xalacom
- monopost
- Monopost
- xalatan
- Xalatan
- xelpros
- Xelpros
- 5 heptenoic acid 7 3 5 dihydroxy 2 3 hydroxy 5 phenylpentyl cyclopentyl 1 methylethyl ester 1r 1 alpha z 2 beta r 3 alpha 5 alpha
- 5-HEPTENOIC ACID, 7-(3,5-DIHYDROXY-2-(3-HYDROXY-5-PHENYLPENTYL)CYCLOPENTYL)-1-METHYLETHYL ESTER, (1R-(1.ALPHA.(Z),2.BETA.(R*),3.ALPHA.,5.ALPHA.))-
- bimatoporost latanoprost
- Bimatoporost-Latanoprost
- iyuzeh
- Iyuzeh
- latanoprost
- Latanoprost
- Latanoprost (isopropyl ester)
- Latanoprost (Xalatan)
- LATANOPROST [EP MONOGRAPH]
- latanoprost [INN]
- LATANOPROST [JAN]
- LATANOPROST [MART.]
- LATANOPROST [MI]
- LATANOPROST [ORANGE BOOK]
- LATANOPROST [USAN]
- LATANOPROST [USP MONOGRAPH]
- LATANOPROST [USP-RS]
- LATANOPROST [VANDF]
- Latanoprost [WHO-DD]
- latanoprost 0.005% (Xalatan)
- Latanoprost 0.005% ophthalmic solution (Xalatan)
- Latanoprost 0.005% Ophthalmic Solution (XALATAN)
- Latanoprost 0.005%, Xalatan®
And 44 more, listed on the interactive page.
- ATC classification codes
- S01EE01
Sources for recorded values
- CAS registry numbers
- 130209-82-4
- ChEMBL ID
- CHEMBL1051
- InChIKey
- GGXICVAJURFBLW-CEYXHVGTSA-N
- PubChem compound IDs
- 5311221
- RxNorm IDs (RxCUI)
- 43611
- FDA ingredient codes (UNII)
- 6Z5B6HVF6O
- Applicant
- UPJOHN
- Approval date
- 5 Jun 1996
- Application number
- NDA020597
- Status
- Authorised
- Status date
- 15 Nov 2023
- Authorisation date
- 15 Nov 2023
- Approved indications
- Catiolanze is indicated for the reduction of elevated intraocular pressure (IOP) in adult patients with open angle glaucoma or ocular hypertension. Catiolanze is indicated for the reduction of elevated IOP in children from 4 years of age and adolescents with elevated IOP and paediatric glaucoma.
- Product number
- EMEA/H/C/005933
- Authorisation holder
- Santen Oy
- Priority medicines scheme
- No
- Generic
- No
- Biosimilar
- No
- Generic medicines
- 0
- Biosimilar medicines
- 0
- Advanced therapy
- No
- Conditional approval
- No
- Additional monitoring
- No
- Accelerated assessment
- No
- Exceptional circumstances
- No
Therapeutic areas
- Glaucoma, Open-Angle
European medicines record
- Patents
- 3
- Designations
- 1
- Earliest recorded loss of exclusivity
- 8 Jul 2031
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- Yes
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Pharmacology name
- latanoprost (isopropyl ester)
- Type
- Synthetic organic
- Drug name stem
- -prost
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- topical
- Mechanism
- Prostanoid FP receptor agonist
- Action type
- Agonist
- Target
- Prostaglandin F2-alpha receptor
- Protein identifier
- P43088
- Action
- Full agonist
- Action type
- FULL_AGONIST
- Target
- FP receptor
- Gene symbol
- PTGFR
- Protein identifier
- P43088
- Median affinity
- 6.3
- Affinity units
- pKi
- Primary target
- Yes
Open Targets mechanisms
- Mechanism
- Prostanoid FP receptor agonist
- Action type
- Agonist
- Target
- Prostaglandin F2-alpha receptor
DrugCentral mechanisms
- Action type
- Agonist
- Gene symbol
- PTGFR
- Protein identifier
- P43088
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Hypertension
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000537
- Subject identifier
- D006973
- Condition
- Glaucoma, Open-Angle
- Highest recorded phase
- 4
- Condition identifier
- EFO:0004190
- Subject identifier
- D005902
- Condition
- Alopecia Areata
- Highest recorded phase
- 1
- Condition identifier
- EFO:0004192
- Subject identifier
- D000506
- Condition
- Vitiligo
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004208
- Subject identifier
- D014820
- Condition
- Meniere Disease
- Highest recorded phase
- 2
- Condition identifier
- EFO:0006862
- Subject identifier
- D008575
- Condition
- Ocular Hypertension
- Highest recorded phase
- 4
- Condition identifier
- EFO:1001069
- Subject identifier
- D009798
- Condition
- Glaucoma
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0005041
- Subject identifier
- D005901
- Condition identifier
- EFO_0000537
- Condition identifier
- EFO_0004190
- Condition identifier
- EFO_0004192
- Condition identifier
- EFO_0004208
- Condition identifier
- EFO_0006862
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001069
- Condition identifier
- HP_0045075
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0001744
- Condition identifier
- MONDO_0001966
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005041
- Condition identifier
- MONDO_0005041
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005044
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005266
- Condition identifier
- MONDO_0005338
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005339
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005340
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0006837
- Condition identifier
- MONDO_0006875
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0007972
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0008327
- Condition identifier
- MONDO_0008661
- Highest recorded phase
- 2
- Event
- blepharitis
- Reports
- 39
- Reporting signal score
- 97.6774
- Event
- blindness
- Reports
- 82
- Reporting signal score
- 92.4217
- Event
- cataract
- Reports
- 146
- Reporting signal score
- 205.934
- Event
- cataract operation
- Reports
- 32
- Reporting signal score
- 64.9805
- Event
- choroidal detachment
- Reports
- 26
- Reporting signal score
- 84.5608
- Event
- choroidal effusion
- Reports
- 29
- Reporting signal score
- 90.6407
- Event
- conjunctival hyperaemia
- Reports
- 48
- Reporting signal score
- 113.487
- Event
- corneal disorder
- Reports
- 39
- Reporting signal score
- 108.558
- Event
- corneal oedema
- Reports
- 30
- Reporting signal score
- 64.4767
- Event
- corneal opacity
- Reports
- 25
- Reporting signal score
- 65.3457
- Event
- cystoid macular oedema
- Reports
- 33
- Reporting signal score
- 81.8376
- Event
- diarrhoea
- Reports
- 36
- Reporting signal score
- 113.166
- Event
- dry eye
- Reports
- 120
- Reporting signal score
- 197.038
- Event
- erythema of eyelid
- Reports
- 34
- Reporting signal score
- 76.9022
- Event
- eye allergy
- Reports
- 25
- Reporting signal score
- 87.8595
- Event
- eye discharge
- Reports
- 36
- Reporting signal score
- 65.6973
- Event
- eye disorder
- Reports
- 101
- Reporting signal score
- 170.12
- Event
- eye irritation
- Reports
- 649
- Reporting signal score
- 2,177.95
- Event
- eye pain
- Reports
- 363
- Reporting signal score
- 931.179
- Event
- eye pruritus
- Reports
- 142
- Reporting signal score
- 307.851
- Event
- eye swelling
- Reports
- 79
- Reporting signal score
- 98.9926
- Event
- fatigue
- Reports
- 46
- Reporting signal score
- 108.315
- Event
- foreign body sensation in eyes
- Reports
- 70
- Reporting signal score
- 223.499
- Event
- glaucoma
- Reports
- 176
- Reporting signal score
- 440.033
- Event
- growth of eyelashes
- Reports
- 34
- Reporting signal score
- 147.565
And 22 more, listed on the interactive page.
- NCT00051142
- NCT00051155
- NCT00051181
- NCT00150267
- NCT00159653
- NCT00219596
- NCT00230763
- NCT00277498
- NCT00283764
- NCT00293787
- NCT00293800
- NCT00311389
- NCT00650338
- NCT00751127
- NCT00868894
- NCT01162603
- NCT01223378
- NCT01229982
- NCT01655758
- NCT01896180
- NCT01917383
- NCT01987323
- NCT02014142
- NCT02531152
- NCT02829996
And 46 more, listed on the interactive page.
- Dose
- One drop
- Route
- Topical
- How often
- Once daily
- Remove contact lenses before use
- Wait 15 minutes after administration to reinsert contact lenses
- Hydrogen bond acceptors
- 5
- Hydrogen bond donors
- 3
- Polar surface area
- 86.99
- Calculated partition coefficient (ALogP)
- 4.19
- Calculated partition coefficient (XLogP)
- 4.3
- Prodrug
- Yes
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 13
- Heavy atoms
- 31
- Molecular formula
- C26H40O5
- Monoisotopic mass
- 432.28757437
- Natural product
- Yes
- 24208-463
- 25021-001
- 42571-499
- 47335-317
- 58151-419
- 61314-547
- 64980-516
- 65862-872
- 68083-609
- 68462-944
- 70069-421
- 70756-680
- 71205-154
- 82584-003
- 50090-1920
- 50090-7062
- 59762-0333
- 68071-2376
- 68071-3884
- Recorded assays
- 447
- Active assays
- 10
- Confirmatory
- Other
- Screening
- Ophthalmic Solutions
Related records
Trials (230)
- 0.005% Latanoprost Gel for Nonsegmental Vitiligo
- 24-hour Control of Intraocular Pressure (IOP) in Ocular Hypertension
- 24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients
- 24-Hour Intraocular Pressure (IOP) And Blood Pressure Control In Glaucoma And Ocular Hypertension Patients
- 24-Hour Intraocular Pressure Control With Bimatoprost/Timolol Versus Latanoprost as First Choice
- 24-hour Study of Dorzolamide/Timolol and Latanoprost/Timolol Fixed Combinations
- 24-hr IOP With Travoprost/Timolol Compared With Latanoprost/Timolol in XFG
- 28-Day Repeated Topical Study to Evaluate the Safety and Activity of 5 Escalating Dose Levels of SAR366234 and One Dose of Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension
- A 12 Week Comparison of DuoTrav and Xalacom in Open-Angle Glaucoma
- A 12-Month Study to Evaluate the Efficacy and Safety of Once-Daily Instillation of Combination Glaucoma Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension
- A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma
- A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Evening Dosing With Xalacom In Subjects With Glaucoma
- A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma
- A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
- A 5-Year Postmarketing Safety Study Of Xalcom In Patients With Open Angle Glaucoma Or Ocular Hypertension
- A 6 Month Study Comparing Latanoprost With Timolol in Patients With Open Angle Glaucoma or Ocular Hypertension
- A 6-Week Safety and Efficacy Study of Travatan Compared to Xalcom in Subjects With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT)
- A Clinical Study to Evaluate the Efficacy and Safety of CKD-351
- A Clinical Study to Evaluate the Efficacy and Safety of CKD-351
- A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Patients With Primary Open Angle Glaucoma
Approved for (4)
In development for (3)
- Alopecia areata Phase 1
- Meniere disease Phase 2
- Vitiligo Phase 2
Targets (1)
- PTGFR Prostanoid FP receptor agonist